Fairvalue-Calculator Fairvalue-Calculator
EN DE

TransMedics Group (TMDX) Fair Value & Analysis

Healthcare · US · Market cap $2.5B

Price$73.83
Fair Value$61.32
Upside-16.9%
Quality95/100
Evidence: High Range $45.14 – $134.51

Fair value as of: Jun 24, 2026

Analysis

TransMedics Group (TMDX) currently trades at $73.83, while our model-based Fair Value estimate is $61.32 — implying the stock looks roughly 16.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ ma…

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABTT34) -20% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -27% Boston Scientific Corporation (B1SX34) -5% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is TransMedics Group (TMDX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $61.32 versus a price of $73.83 — about −17% (overvalued). Model-based estimate, not financial advice.
What is the fair value of TMDX?
Our 21-model fair value for TransMedics Group is $61.32 (as of Jun 24, 2026), built from audited fundamentals. The current price is $73.83.
What is the quality score of TMDX?
TransMedics Group has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.